Phase 3 Readout
ERAS: Phase 3 Topline: A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metasta
December 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2028
- Company
- Erasca, Inc. (ERAS)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metasta
- Company
- Erasca, Inc. (ERAS)
- Indication
- Advanced or Metastatic NRAS-mutant Melanoma